- Home
- SNT vs PEPG Comparison
SNT vs PEPG Comparison
Compare SNT & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- PEPG
- Stock Information
- Founded
- SNT 1965
- PEPG 2018
- Country
- SNT Canada
- PEPG United States
- Employees
- SNT N/A
- PEPG N/A
- Industry
- SNT Telecommunications Equipment
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- PEPG Health Care
- Exchange
- SNT Nasdaq
- PEPG Nasdaq
- Market Cap
- SNT 78.3M
- PEPG 64.2M
- IPO Year
- SNT 1993
- PEPG 2022
- Fundamental
- Price
- SNT $3.93
- PEPG $1.37
- Analyst Decision
- SNT
- PEPG Buy
- Analyst Count
- SNT 0
- PEPG 3
- Target Price
- SNT N/A
- PEPG $14.67
- AVG Volume (30 Days)
- SNT 49.5K
- PEPG 482.2K
- Earning Date
- SNT 11-12-2024
- PEPG 03-05-2025
- Dividend Yield
- SNT N/A
- PEPG N/A
- EPS Growth
- SNT N/A
- PEPG N/A
- EPS
- SNT 0.06
- PEPG N/A
- Revenue
- SNT $34,455,000.00
- PEPG N/A
- Revenue This Year
- SNT N/A
- PEPG N/A
- Revenue Next Year
- SNT N/A
- PEPG N/A
- P/E Ratio
- SNT $66.81
- PEPG N/A
- Revenue Growth
- SNT 2.04
- PEPG N/A
- 52 Week Low
- SNT $1.08
- PEPG $1.16
- 52 Week High
- SNT $3.97
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- SNT 62.97
- PEPG 31.82
- Support Level
- SNT $3.40
- PEPG $1.16
- Resistance Level
- SNT $3.90
- PEPG $1.60
- Average True Range (ATR)
- SNT 0.23
- PEPG 0.14
- MACD
- SNT 0.02
- PEPG 0.11
- Stochastic Oscillator
- SNT 92.97
- PEPG 48.28
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.